Articles by Anna Rose Welch

71. FDA News Roundup: Novo Nordisk, AstraZeneca, Merck, And More 4/10/2015

    What FDA decisions did you miss this week?

72. Where Did The Biobetters Buzz Go? 4/2/2015

    The past few weeks, it seems the word on everyone’s tongue — including my own — has been biosimilars. Since the approval of Novartis’ Zarzio in the U.S., there’s been a lot of discussion and speculation about how this important approval will affect current blockbusters on the market and who will enter the space next. But I’m left with another question: What happened to the buzz over biobetters?

73. FDA, EMA Drug Approval Stats: Are We Measuring Success The Wrong Way? 3/27/2015

    While approval stats spark declarations of excitement from each regulatory agency and make news headlines, the differences in approval times in particular aren’t necessarily a cause for celebration; rather, they illuminate something much more concerning about the state of global drug development.

74. How Will AbbVie, J&J, And Amgen Handle The Biosimilar Age? 3/20/2015

    Following the approval of the first biosimilar last week, there were a number of questions circulating throughout the industry. My blog from last week addressed two questions about where the biosimilars market is headed, but I also wanted to address a third question I’ve seen cropping up: What are companies with blockbusters going to do to keep revenues intact now that they’re facing biosimilar competition?

75. Who To Watch In The Alzheimer's Treatment And Research Space 3/13/2015

    In an interview with the Triangle Business Journal, Eli Lilly CEO John Lechleiter said 2/3 of drugs fail to show efficacy in Phase 2 trials because there isn’t enough understanding of the targeted disease. He tells the Journal, “While drug hunting remains a vital activity… I think we need to advance, like our ancestors did, from hunting to farming, cultivating the knowledge of disease.”

76. FDA News Roundup: Bristol-Myers Squibb, Bayer, Astellas, And More 3/11/2015

    What FDA decisions have you missed in the last week?

77. FDA News Roundup: Shire, Bristol-Myers Squibb, Alexion, And More 3/6/2015

    What FDA decisions did you miss this week?

78. FDA News Roundup: Pfizer, Novartis, Sanofi, and More 3/2/2015

    What drug approvals have you missed recently?

79. 5 Trends Poised To Accelerate Drug Development 2/27/2015

    In November 2014, Tufts Center for Drug Discovery announced it takes $2.6 billion to push a drug through development and marketing approval — a process that often spans longer than 10 years.

80. Who Is Forging Ahead In The MS Treatment Space? 2/18/2015

    The NIH estimates roughly $103 million of its budget will be spent on multiple sclerosis research in 2015. That seems like a small amount of money when it comes to the size of its $40 billion budget.  But in doing some digging around, I’m seeing signs that there are actually quite a few players — big and small — in the academic, bio, and pharma realms working in the MS treatment space to benefit the 400,000 U.S. and 2.3 million patients globally.